600 related articles for article (PubMed ID: 26188543)
21. Estimation from moments measurements for amyloid depolymerisation.
Armiento A; Doumic M; Moireau P; Rezaei H
J Theor Biol; 2016 May; 397():68-88. PubMed ID: 26953651
[TBL] [Abstract][Full Text] [Related]
22. Mysterious oligomerization of the amyloidogenic proteins.
Uversky VN
FEBS J; 2010 Jul; 277(14):2940-53. PubMed ID: 20546306
[TBL] [Abstract][Full Text] [Related]
23. Influence of the β-sheet content on the mechanical properties of aggregates during amyloid fibrillization.
Ruggeri FS; Adamcik J; Jeong JS; Lashuel HA; Mezzenga R; Dietler G
Angew Chem Int Ed Engl; 2015 Feb; 54(8):2462-6. PubMed ID: 25588987
[TBL] [Abstract][Full Text] [Related]
24. A covalent homodimer probing early oligomers along amyloid aggregation.
Halabelian L; Relini A; Barbiroli A; Penco A; Bolognesi M; Ricagno S
Sci Rep; 2015 Sep; 5():14651. PubMed ID: 26420657
[TBL] [Abstract][Full Text] [Related]
25. Structural features and cytotoxicity of amyloid oligomers: implications in Alzheimer's disease and other diseases with amyloid deposits.
Stefani M
Prog Neurobiol; 2012 Dec; 99(3):226-45. PubMed ID: 22450705
[TBL] [Abstract][Full Text] [Related]
26. How do membranes initiate Alzheimer's Disease? Formation of toxic amyloid fibrils by the amyloid β-protein on ganglioside clusters.
Matsuzaki K
Acc Chem Res; 2014 Aug; 47(8):2397-404. PubMed ID: 25029558
[TBL] [Abstract][Full Text] [Related]
27. Camelid single-domain antibody fragments: Uses and prospects to investigate protein misfolding and aggregation, and to treat diseases associated with these phenomena.
Pain C; Dumont J; Dumoulin M
Biochimie; 2015 Apr; 111():82-106. PubMed ID: 25656912
[TBL] [Abstract][Full Text] [Related]
28. Protein misfolding, aggregation and mechanism of amyloid cytotoxicity: An overview and therapeutic strategies to inhibit aggregation.
Zaman M; Khan AN; Wahiduzzaman ; Zakariya SM; Khan RH
Int J Biol Macromol; 2019 Aug; 134():1022-1037. PubMed ID: 31128177
[TBL] [Abstract][Full Text] [Related]
29. Intermediates caught in the act: tracing insulin amyloid fibril formation in time by combined optical spectroscopy, light scattering, mass spectrometry and microscopy.
Gladytz A; Lugovoy E; Charvat A; Häupl T; Siefermann KR; Abel B
Phys Chem Chem Phys; 2015 Jan; 17(2):918-27. PubMed ID: 25408431
[TBL] [Abstract][Full Text] [Related]
30. Resonance Raman spectroscopic measurements delineate the structural changes that occur during tau fibril formation.
Ramachandran G; Milán-Garcés EA; Udgaonkar JB; Puranik M
Biochemistry; 2014 Oct; 53(41):6550-65. PubMed ID: 25284680
[TBL] [Abstract][Full Text] [Related]
31. A minimal conformational switching-dependent model for amyloid self-assembly.
Ranganathan S; Ghosh D; Maji SK; Padinhateeri R
Sci Rep; 2016 Feb; 6():21103. PubMed ID: 26883720
[TBL] [Abstract][Full Text] [Related]
32. Cooperative structural transitions in amyloid-like aggregation.
Steckmann T; Bhandari YR; Chapagain PP; Gerstman BS
J Chem Phys; 2017 Apr; 146(13):135103. PubMed ID: 28390382
[TBL] [Abstract][Full Text] [Related]
33. Structural properties and dynamic behavior of nonfibrillar oligomers formed by PrP(106-126).
Walsh P; Neudecker P; Sharpe S
J Am Chem Soc; 2010 Jun; 132(22):7684-95. PubMed ID: 20465257
[TBL] [Abstract][Full Text] [Related]
34. Structure-Based Peptide Design to Modulate Amyloid Beta Aggregation and Reduce Cytotoxicity.
Kumar J; Namsechi R; Sim VL
PLoS One; 2015; 10(6):e0129087. PubMed ID: 26070139
[TBL] [Abstract][Full Text] [Related]
35. Strain-specific Fibril Propagation by an Aβ Dodecamer.
Dean DN; Das PK; Rana P; Burg F; Levites Y; Morgan SE; Ghosh P; Rangachari V
Sci Rep; 2017 Jan; 7():40787. PubMed ID: 28098204
[TBL] [Abstract][Full Text] [Related]
36. Structural mechanisms of oligomer and amyloid fibril formation by the prion protein.
Sengupta I; Udgaonkar JB
Chem Commun (Camb); 2018 Jun; 54(49):6230-6242. PubMed ID: 29789820
[TBL] [Abstract][Full Text] [Related]
37. The native state of prion protein (PrP) directly inhibits formation of PrP-amyloid fibrils in vitro.
Honda RP; Kuwata K
Sci Rep; 2017 Apr; 7(1):562. PubMed ID: 28373719
[TBL] [Abstract][Full Text] [Related]
38. Understanding amyloid fibril nucleation and aβ oligomer/drug interactions from computer simulations.
Nguyen P; Derreumaux P
Acc Chem Res; 2014 Feb; 47(2):603-11. PubMed ID: 24368046
[TBL] [Abstract][Full Text] [Related]
39. Protein misfolded oligomers: experimental approaches, mechanism of formation, and structure-toxicity relationships.
Bemporad F; Chiti F
Chem Biol; 2012 Mar; 19(3):315-27. PubMed ID: 22444587
[TBL] [Abstract][Full Text] [Related]
40. Preparation of Stable Amyloid-β Oligomers Without Perturbative Methods.
Kotler SA; Ramamoorthy A
Methods Mol Biol; 2018; 1777():331-338. PubMed ID: 29744846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
